418,505 Shares in Exagen Inc. (NASDAQ:XGN) Bought by Driehaus Capital Management LLC

Driehaus Capital Management LLC bought a new stake in shares of Exagen Inc. (NASDAQ:XGN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 418,505 shares of the company's stock, valued at approximately $1,716,000. Driehaus Capital Management LLC owned about 2.37% of Exagen as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of XGN. Palumbo Wealth Management LLC lifted its position in Exagen by 13.5% during the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company's stock valued at $355,000 after acquiring an additional 10,340 shares during the last quarter. Corient Private Wealth LLC acquired a new position in Exagen during the 4th quarter valued at approximately $45,000. Virtu Financial LLC acquired a new position in Exagen during the 4th quarter valued at approximately $46,000. Geode Capital Management LLC increased its stake in Exagen by 11.9% during the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock valued at $402,000 after purchasing an additional 10,442 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its stake in Exagen by 8.8% during the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company's stock valued at $756,000 after purchasing an additional 14,920 shares in the last quarter. Hedge funds and other institutional investors own 75.25% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on XGN. Cantor Fitzgerald restated an "overweight" rating and set a $8.00 price target on shares of Exagen in a research note on Monday, January 13th. BTIG Research restated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. Finally, William Blair reiterated an "outperform" rating on shares of Exagen in a research note on Wednesday, March 12th.

Exagen Stock Performance

Shares of NASDAQ:XGN traded up $0.06 during midday trading on Monday, reaching $5.77. The company's stock had a trading volume of 198,080 shares, compared to its average volume of 109,025. The firm has a market capitalization of $103.87 million, a PE ratio of -6.14 and a beta of 1.50. Exagen Inc. has a twelve month low of $1.49 and a twelve month high of $7.20. The stock has a fifty day moving average of $4.60 and a 200 day moving average of $4.15. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54.

Exagen (NASDAQ:XGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.20). Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The firm had revenue of $15.50 million for the quarter, compared to analyst estimates of $14.55 million. During the same quarter in the prior year, the business earned ($0.19) earnings per share. On average, equities analysts expect that Exagen Inc. will post -0.88 EPS for the current fiscal year.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).